{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-025248","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.341082+00:00","generated_at":"2026-05-26T05:57:56.249956+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Crinetics appoints Tobin Schilke as CFO effective Feb 28, 2025","bullets":["Tobin Schilke appointed CFO effective February 28, 2025, succeeding Marc Wilson.","Schilke was previously CFO at Revance Therapeutics (2018-2025) and Achaogen.","Base salary $540,000; target bonus 40% of salary; inducement grant of 52,000 RSUs and option for 80,000 shares.","Marc Wilson's departure was previously announced in August 2024 for personal reasons."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-025248","json":"https://secwatch.observer/filing/0000950170-25-025248.json","markdown":"https://secwatch.observer/filing/0000950170-25-025248.md","text":"https://secwatch.observer/filing/0000950170-25-025248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025025248/0000950170-25-025248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025025248/crnx-20250221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:57:56.249956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68f40ff889","claim":"Tobin \"Toby\" Schilke was appointed as Chief Financial Officer at Crinetics Pharmaceuticals, Inc..","evidence_excerpt":"On February 24, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Tobin “Toby” Schilke as Chief Financial Officer, which will be effective as of February 28, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025025248/0000950170-25-025248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}